Related references
Note: Only part of the references are listed.Feasibility of withholding dexamethasone premedication for hypersensitivity reactions associated with paclitaxel administration
Walailuk Tanpipattanakul et al.
ASIAN BIOMEDICINE (2016)
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Michael J. Berger et al.
SUPPORTIVE CARE IN CANCER (2015)
A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms
E. Piovano et al.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2012)
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Michael J. Berger et al.
SUPPORTIVE CARE IN CANCER (2012)
Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center
Lincy S. Lal et al.
SUPPORTIVE CARE IN CANCER (2009)
Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy
T Sendo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration
AS Braverman et al.
CHEMOTHERAPY (2005)
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial
P Kosmidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Premedication strategy for weekly paclitaxel
J Quock et al.
CANCER INVESTIGATION (2002)
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel
JS Kwon et al.
GYNECOLOGIC ONCOLOGY (2002)
Dose reduction of steroid premeditation for paclitaxel:: No increase of hypersensitivity reactions
H Köppler et al.
ONKOLOGIE (2001)
Role of formulation vehicles in taxane pharmacology
L van Zuylen et al.
INVESTIGATIONAL NEW DRUGS (2001)
Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients
L van Zuylen et al.
ANTI-CANCER DRUGS (2000)
Paclitaxel-associated hypersensitivity reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
